Li-Ru He

691 total citations
19 papers, 591 citations indexed

About

Li-Ru He is a scholar working on Surgery, Molecular Biology and Oncology. According to data from OpenAlex, Li-Ru He has authored 19 papers receiving a total of 591 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Surgery, 9 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Li-Ru He's work include Esophageal Cancer Research and Treatment (8 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Epigenetics and DNA Methylation (4 papers). Li-Ru He is often cited by papers focused on Esophageal Cancer Research and Treatment (8 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Epigenetics and DNA Methylation (4 papers). Li-Ru He collaborates with scholars based in China, Hong Kong and United States. Li-Ru He's co-authors include Dan Xie, Yi-Xin Zeng, Xin‐Yuan Guan, Yi-Ji Liao, Meng‐Zhong Liu, Mu-Yan Cai, Hsiang‐Fu Kung, Lei Zhao, Mian Xi and Qiao-Qiao Li and has published in prestigious journals such as Cancer Research, Scientific Reports and Molecular Cancer.

In The Last Decade

Li-Ru He

19 papers receiving 586 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Li-Ru He China	14	422	189	170	96	94	19	591
Yingqi Zhou China	12	358 0.8×	225 1.2×	204 1.2×	112 1.2×	65 0.7×	20	577
Cristina Niccoli Italy	11	156 0.4×	129 0.7×	150 0.9×	72 0.8×	140 1.5×	19	393
Qingsi He China	13	247 0.6×	145 0.8×	97 0.6×	146 1.5×	100 1.1×	34	509
Kotaro Mizuno Japan	10	280 0.7×	102 0.5×	164 1.0×	58 0.6×	173 1.8×	38	548
Mariangela Balistreri Italy	10	270 0.6×	219 1.2×	124 0.7×	72 0.8×	89 0.9×	15	487
Zhiming Wang China	15	402 1.0×	320 1.7×	154 0.9×	41 0.4×	80 0.9×	32	638
Ji-Hai Yu China	12	276 0.7×	143 0.8×	140 0.8×	42 0.4×	46 0.5×	19	483
Jue‐Yu Zhou China	15	426 1.0×	278 1.5×	110 0.6×	38 0.4×	54 0.6×	42	591
Shoichiro Mukai Japan	12	173 0.4×	97 0.5×	117 0.7×	90 0.9×	111 1.2×	54	438

Countries citing papers authored by Li-Ru He

Since Specialization

Citations

This map shows the geographic impact of Li-Ru He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Li-Ru He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Li-Ru He more than expected).

Fields of papers citing papers by Li-Ru He

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Li-Ru He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Li-Ru He. The network helps show where Li-Ru He may publish in the future.

Co-authorship network of co-authors of Li-Ru He

This figure shows the co-authorship network connecting the top 25 collaborators of Li-Ru He. A scholar is included among the top collaborators of Li-Ru He based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Li-Ru He. Li-Ru He is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Li, Yang, Li-Ru He, Ying Gao, et al.. (2019). CHD1L contributes to cisplatin resistance by upregulating the ABCB1–NF-κB axis in human non-small-cell lung cancer. Cell Death and Disease. 10(2). 99–99. 37 indexed citations

He, Li-Ru, Wei Qiao, Zhongxing Liao, et al.. (2015). Impact of comorbidities and use of common medications on cancer and non-cancer specific survival in esophageal carcinoma. BMC Cancer. 15(1). 1095–1095. 13 indexed citations

Zhao, Lei, Mian Xi, Li-Ru He, et al.. (2015). Association of insulin-like growth factor-binding protein-3 with radiotherapy response and prognosis of esophageal squamous cell carcinoma. Chinese Journal of Cancer. 34(3). 514–21. 15 indexed citations

Zhao, Lei, Feng Chi, Mian Xi, et al.. (2015). Polymorphisms of insulin-like growth factor binding protein-3 as a predictor for risk and patient survival in esophageal squamous cell carcinoma. Biomedicine & Pharmacotherapy. 74. 148–152. 4 indexed citations

Zhao, Lei, Yingxue Wang, Xiao-Peng Tian, et al.. (2015). Insulin-like growth factor binding protein-3 is a new predictor of radiosensitivity on esophageal squamous cell carcinoma. Scientific Reports. 5(1). 17336–17336. 15 indexed citations

He, Li-Ru, Ning-Fang Ma, Jie-Wei Chen, et al.. (2015). Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival. Oncotarget. 6(31). 31181–31190. 21 indexed citations

Zhang, Peng, Mian Xi, Qiao-Qiao Li, et al.. (2014). The Modified Glasgow Prognostic Score Is an Independent Prognostic Factor in Patients with Inoperable Thoracic Esophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy. Journal of Cancer. 5(8). 689–695. 39 indexed citations

Zhang, Peng, Mian Xi, Lei Zhao, et al.. (2014). Efficacy and prognostic analysis of chemoradiotherapy in patients with thoracic esophageal squamous carcinoma with cervical lymph nodal metastasis alone. Radiation Oncology. 9(1). 256–256. 6 indexed citations

Xu, Chuan, Dan Xie, Shi‐Cang Yu, et al.. (2013). β-Catenin/POU5F1/SOX2 Transcription Factor Complex Mediates IGF-I Receptor Signaling and Predicts Poor Prognosis in Lung Adenocarcinoma. Cancer Research. 73(10). 3181–3189. 79 indexed citations

10.

Qian, Dong, Li-Ru He, Frank Yonghong Li, et al.. (2013). PinX1 suppresses bladder urothelial carcinoma cell proliferation via the inhibition of telomerase activity and p16/cyclin D1 pathway. Molecular Cancer. 12(1). 148–148. 28 indexed citations

11.

Zhao, Lei, Qiao-Qiao Li, Rui Zhang, et al.. (2012). The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin. Tumor Biology. 33(4). 1115–1123. 12 indexed citations

12.

Zhao, Lei, Li-Ru He, Mian Xi, et al.. (2012). Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3. Journal of Translational Medicine. 10(1). 249–249. 36 indexed citations

13.

Cao, Xun, Yong Li, Rong-Zhen Luo, et al.. (2012). Tyrosine-Protein Phosphatase Nonreceptor Type 12 Is a Novel Prognostic Biomarker for Esophageal Squamous Cell Carcinoma. The Annals of Thoracic Surgery. 93(5). 1674–1680. 26 indexed citations

14.

Zhao, Lei, Li-Ru He, Rui Zhang, et al.. (2011). Low expression of IGFBP-3 predicts poor prognosis in patients with esophageal squamous cell carcinoma. Medical Oncology. 29(4). 2669–2676. 18 indexed citations

15.

Cai, Mu-Yan, Li-Ru He, Shi-Juan Mai, et al.. (2010). EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-β1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis. 31(9). 1576–1583. 119 indexed citations

16.

Huang, Liang, Li Wang, Binkui Li, et al.. (2010). Prognostic value of Wnt inhibitory factor-1 expression in hepatocellular carcinoma that is independent of gene methylation. Tumor Biology. 32(1). 233–240. 12 indexed citations

17.

Cai, Mu-Yan, Li-Ru He, Junhang Luo, et al.. (2010). Intensive expression of Bmi-1 is a new independent predictor of poor outcome in patients with ovarian carcinoma. BMC Cancer. 10(1). 133–133. 48 indexed citations

18.

Liao, Yi-Ji, Li-Ru He, Yangchao Chen, et al.. (2010). PYRIN domain of NALP2 inhibits cell proliferation and tumor growth of human glioblastoma. Plasmid. 64(1). 41–50. 11 indexed citations

19.

He, Li-Ru, Meng‐Zhong Liu, Binkui Li, et al.. (2009). Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma. BMC Cancer. 9(1). 461–461. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact